FinancialContent

Articles published by Terns Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
News headline image
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Announces Leadership Transition
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
News headline image
Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
< Previous 1 2 3 Next >